Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?

By The Motley Fool5 days ago

AD

We've known for a while that the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) was highly effective in individuals ages 16 and up. The two partners recently announced an impressive 100% efficacy for the vaccine in children between the ages of 12 and 15. In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli discuss why neither of these stocks soared after the news about this great efficacy in kids.

10 stocks we like better than Pfizer

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

Continue read on nasdaq.com